

**26-APR-2018 6:10  
CANCER CONTROL ACCRUAL REPORT**

STUDY	O R P E E G N	ARM	TOTAL	REGS.	REGS.	REGS.	REGS.	REGS.	ADMIN	
			REGS.	LAST Month	LAST Month	LAST Month	LAST Month	LAST Month		LAST Month
S1007-Breast,Adj,N1,Endocrine+/-Chemo	1	Y 1	Recurrence Score testing	9383	327	0	0	0	0	BREAST
				9383	327	0	0	0	0	
	2	Y 2	Chemo and Endocrine Therapy	2547	122	0	0	0	0	
			3	Endocrine Therapy Alone	2536	121	0	0	0	0
					5083	243	0	0	0	0
S1207-Brst,Adj,Endocrine+/-Everolimus	1	Y 1	Blinded drug + Endocrine	785	185	93	49	18	2	BREAST
			2	Blinded drug + Endocrine	791	198	90	44	16	1
					1576	383	183	93	34	3
S1316-Compar. Effectiv. Trial for MBO	1	T 1	Randomization Surgery	5	4	2	1	0	0	SURV
			2	Randomization Non-surgical M	5	5	4	0	0	0
			3	Patient Choice Surgery	45	22	9	8	1	0
			4	Patient Choice Non-surgical M	100	49	22	12	2	0
					155	80	37	21	3	0
S1415CD-TrACER CSF Standing Order Intervention for FN	1	Y 1	Site assigned to Cohort	454	288	123	65	24	7	CCD
			2	Site randomized: Control	307	251	108	45	15	1
			3	SiteRand Int Risk: CSF	525	446	259	127	41	5
			4	SiteRand Int Risk: No CSF	395	358	189	112	52	7
					1681	1343	679	349	132	20
S1417CD-Colorectal, Cost Cohort Study	1	Y 1	Observation	232	191	110	67	23	2	CCD
				232	191	110	67	23	2	
S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab)	1	Y 1	Tissue for PD-L1 testing	205	187	112	62	15	4	BREAST
				205	187	112	62	15	4	
	2	Y 2	Observation	92	88	53	30	14	0	
			3	MK-3475 (Pembrolizumab)	86	80	46	28	6	0
					178	168	99	58	20	0
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol	1	Y 0	Screening	6	6	6	2	0	0	SURV
				6	6	6	2	0	0	
	2	Y 1	Carvedilol	2	2	2	1	0	0	
			2	No intervention	3	3	3	2	1	0
			3	Observation	1	1	1	0	0	0

**26-APR-2018 6:10  
CANCER CONTROL ACCRUAL REPORT**

STUDY	O R P E E G N	ARM	REGS.					ADMIN
			TOTAL REGS.	LAST Month	LAST Month	LAST Month	LAST DAYS	
			6	6	6	3	1	0
S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	1 Y 1	TICE BCG	32	29	17	9	3	0 GU
		2 Tokyo-172 BCG	31	29	17	10	5	1
		3 Prime + Tokyo-172 BCG	29	28	15	8	3	0
			<u>92</u>	<u>86</u>	<u>49</u>	<u>27</u>	<u>11</u>	<u>1</u>
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac	0 Y 0	Pre-Registration	489	147	78	24	14	0 PREV
			<u>489</u>	<u>147</u>	<u>78</u>	<u>24</u>	<u>14</u>	<u>0</u>
	1 Y 1	Blinded drug	59	23	14	9	3	0
		2 Blinded drug	36	0	0	0	0	0
		3 Blinded drug	35	0	0	0	0	0
		4 Blinded drug	62	27	14	5	2	0
			<u>192</u>	<u>50</u>	<u>28</u>	<u>14</u>	<u>5</u>	<u>0</u>